Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Cytokinetics (NASDAQ:CYTK)

Galecto, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Galecto, Inc. (the 'Company” or 'Galecto”) (Nasdaq: GLTO) today announced that the Company’s Board of Directors approved the grant...

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

SOUTH SAN FRANCISCO, Calif., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on December 15, 2025 it granted stock options to purchase an aggregate of 21,399 shares of common stock and 14,422 restricted stock units…

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Cytokinetics (NASDAQ:CYTK)

SOUTH SAN FRANCISCO, Calif., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that on December 15, 2025 it granted stock options to purchase an aggregate of 21,399 shares of common stock and 14,422 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting to 10 employees, whose employment commenced in November and December 2025 as a material inducement to their employment.…

Inhibrx pushes two experimental cancer drugs through mid-stage trials

Inhibrx nears full enrollment in a 60-patient INBRX-106 HNSCC study and wraps two ozekibart cohorts, with key 2026 data to guide next FDA steps.